Novo Nordisk launches Ozempic DTC campaign for type 2 Diabetes
Shots:
- The intense market competition leads Novo to focus direct-to-consumer campaign for Ozempic- a once weekly Injectable Type 2 diabetes
- First sales through total diabetic care fell 5% y-o-y with 8% decline in profit
- GLP-1 has shown bright spot in Novo Nordisk’s portfolio- with increase of sale 20% in US and 12% outside US
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
